EXELIXIS, INC. Logo

EXELIXIS, INC.

Oncology-focused biotech that discovers, develops, and commercializes cancer therapies.

EXEL | US

Overview

Corporate Details

ISIN(s):
US30161Q1040
LEI:
Country:
United States of America
Address:
1851 HARBOR BAY PARKWAY, 94502 ALAMEDA

Description

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes therapies for cancer treatment. The company's primary commercial product is cabozantinib, a small molecule inhibitor marketed for multiple cancer indications, including neuroendocrine tumors and certain types of carcinoma. Leveraging a genomics-based approach, Exelixis advances a diverse pipeline of potential medicines. Its research and development programs encompass in-house small molecule discovery and an expanding portfolio of biotherapeutics, such as antibody-drug conjugates and bispecific antibodies. The company pursues both next-generation approaches to established targets and first-in-class opportunities to address unmet needs in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 16:30 English 7.3 KB
2025-11-12 15:10 English 7.3 KB
2025-11-07 22:07
8-K
English 233.0 KB
2025-11-04 22:30
10-Q
English 1.6 MB
2025-11-04 22:25
8-K
English 303.1 KB
2025-10-11 00:57
FORM 4
English 7.4 KB
2025-08-29 23:10
8-K
English 233.5 KB
2025-07-28 22:31
10-Q
English 1.5 MB
2025-07-28 22:09
8-K
English 302.9 KB
2025-06-05 01:57
FORM 4
English 7.7 KB
2025-06-05 01:57
FORM 4
English 7.7 KB
2025-06-03 22:04 English 7.1 KB
2025-06-02 23:22 English 8.5 KB
2025-06-02 22:12 English 7.0 KB
2025-06-02 22:05
8-K
English 237.6 KB

Automate Your Workflow. Get a real-time feed of all EXELIXIS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EXELIXIS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EXELIXIS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.